Asset Details
Do you wish to reserve the book?
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
Do you wish to request the book?
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
2020
Overview
Introduction
Corticosteroids are a mainstay treatment for castration-resistant prostate cancer (CRPC). Although corticosteroids have been associated with adverse events, long-term outcomes related to their sustained use have not been assessed in men with CRPC.
Objective
This study evaluated the impact of cumulative corticosteroid exposure on the risk of developing specific adverse events in men with CRPC.
Methods
Data were obtained from administrative claims databases. Adult chemotherapy-naïve men who initiated CRPC treatment following surgical or medical castration were selected. Patients were grouped into four cohorts based on cumulative corticosteroid dose: no exposure, low exposure (< 0.5 g), medium exposure (0.5–2.0 g), and high exposure (> 2.0 g). Time to each adverse event was assessed using Kaplan–Meier analyses and time-dependent Cox proportional hazard models, adjusting for baseline characteristics.
Results
Overall, 9425 patients were included (no exposure,
N
= 6765; low exposure,
N
= 1660; medium exposure,
N
= 655; high exposure,
N
= 345). The mean age was 71–76 years across cohorts. During the study period, cumulative corticosteroid exposure was associated with a significantly higher risk of developing an infection [high vs. no exposure, adjusted hazard ratio (HR) 2.55; 95% confidence interval (CI) 2.27–2.85;
p
< 0.001 for trend], peptic ulcer (HR 1.91; 95% CI 1.39–2.64;
p
< 0.001), acute cardiovascular events (HR 1.62; 95% CI 1.43–1.83;
p
< 0.001), endocrine disorder (HR 1.61; 95% CI 1.34–1.94;
p
< 0.001), fracture (HR 1.59; 95% CI 1.37–1.86;
p
< 0.001), or mental health condition (HR 1.28; 95% CI 1.06–1.55;
p
= 0.014). Exposure to corticosteroids was associated with a more rapid onset of adverse events.
Conclusion
Patients with CRPC receiving corticosteroids had a higher risk of developing a wide range of adverse events than those not receiving them. The increased adverse event risk was observed after accounting, to the extent possible, for patients’ overall disease severity.
